The content on this site is intended for healthcare professionals only
Dr Stephen Mok speaks to ecancer about giving abatacept after checkpoint inhibitors to improve immunotherapy responses in melanoma.
Combining immune checkpoint inhibitors, such as those targeting CTLA-4 and PD-1, can improve responses over single agents but also increases immune-related side effects.
This study investigated the effects of abatacept when combined with checkpoint inhibitors at different stages over the course of treatment.
Dr Mok explains the methodology of the study saying that in the laboratory melanoma models were treated with either anti-CTLA-4, anti-PD-1 or combination therapy, adding abatacept early during treatment blunted the effects of the checkpoint inhibitors.
Dr Mok says using abatacept after the completion of therapy improved anti-tumour responses; the effects were dependent on stimulation by CD80/86 and the activity of specific T cells called Tregs.
The results suggest a potential combination strategy to improve immunotherapy responses and minimise toxicity.
mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma
Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types
PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma
Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free survival
IO102-IO103 cancer vaccine plus pembrolizumab demonstrates PFS benefit in advanced melanoma
EGFR shows to be a promising therapeutic target in NF1 mutant melanoma
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
